FDA approval likely for drill-free cavity treatment after positive phase 3 trial

A simple, low-cost liquid could spare thousands of children and many adults from painful drilling, anesthesia and emergency dental visits. New U.S. clinical trial data suggest that silver diamine fluoride (SDF), a paint-on treatment used elsewhere for decades, can stop cavities in their tracks with a few quick applications.

The findings, led by researchers at the University of Michigan and published in JAMA Pediatrics, provide the kind of large-scale U.S. evidence regulators and clinicians have wanted. That could clear the way for an FDA approval that would allow wider, more standardized use of this drill-free cavity care.

Key trial results: how effective was the treatment?

A multi-state Phase III clinical trial enrolled hundreds of children under age six to test the effectiveness and safety of 38% SDF applied to decayed baby teeth. The study tracked outcomes when the liquid was reapplied every six months and found significant success in halting progression of cavities.

• Size and scope: The trial included 830 children recruited through dental clinics, pediatric practices and early childhood programs in Michigan, New York and Iowa.
• Outcome: More than half of treated baby teeth showed arrested decay after scheduled SDF treatments, indicating the approach prevents further breakdown of tooth structure without drilling.
• Safety: Investigators reported the treatment was safe even for very young patients, including those around one year old.

How silver diamine fluoride works and what to expect

SDF is applied with a tiny sponge-tipped applicator directly to the cavity surface. It requires no injections, no removal of tooth tissue and can be done quickly in a medical or dental office. The silver component acts as an antimicrobial while the fluoride strengthens tooth structure, together stopping decay activity.

The main cosmetic trade-off is that treated areas typically turn dark where decay has been arrested. Clinicians consider this a minor drawback compared with avoiding pain, infection, or surgery, especially for front-line public health settings and very young children.

Who stands to gain most from SDF treatment

• Young children who can’t tolerate conventional dental procedures
• Older adults with complex medical or mobility issues
• People with developmental or physical disabilities
• Patients with severe dental anxiety or limited access to restorative care

Why FDA approval could be imminent and the regulatory path

In the United States, SDF has been available off-label since 2014 after initial approval as a device for treating tooth sensitivity. However, regulators have sought large U.S.-based trials demonstrating its effectiveness specifically for arresting dental caries before approving it as a drug for cavity treatment.

The new Phase III data provide the clinical evidence a manufacturer can submit in a dental caries drug application to the FDA. The formulation used in this trial—Advantage Arrest 38% SDF—was supplied by the manufacturer, and investigators say the findings support changing the product’s status from off-label use to an approved therapy for cavities.

Implications for clinical practice and health systems

Researchers and pediatric dentistry leaders say gaining formal FDA approval could lead to broader adoption by clinicians, clearer treatment guidelines, and more consistent insurance coverage. That would increase access to effective, conservative cavity care in primary care settings as well as dental offices.

• Public health impact: Tooth decay is the most common chronic childhood disease in the U.S., affecting an estimated 40% or more of kids. Untreated cavities cause pain, infection, missed school days and frequent emergency department visits.
• Access and equity: If pediatricians and family doctors can confidently use or refer for SDF, many cavities could be managed earlier—before they lead to surgery under general anesthesia or repeated medical visits.
• Payment and quality: Approval could prompt insurers to reimburse more consistently and encourage manufacturers to standardize product quality and supply.

Practical considerations: application, frequency and limitations

Clinicians recommend reapplying SDF at regular intervals—often every few months—until the baby tooth naturally exfoliates or until a permanent restorative solution is feasible. For adults, SDF can serve as a long-term management option or as a temporary bridge until definitive care is affordable.

• Application time: Typically only seconds per tooth using a small applicator.
• Repeat visits: Often every 3–6 months depending on the case and clinician judgment.
• Cosmetic effect: Permanent darkening of the treated lesion—acceptable to many families prioritizing pain relief and infection prevention.
• Not a replacement for all restorative care: In many situations, SDF is a tool for arresting decay rather than restoring tooth form and function indefinitely.

Voices from the field and next steps

Study leaders and pediatric dental experts say the data should reassure clinicians and health systems that SDF is both effective and safe for the target pediatric population. They argue that moving SDF from off-label use to an FDA-approved indication would reduce barriers to widespread uptake and standardize treatment across settings.

With the trial results now published in a major peer-reviewed journal and the manufacturer positioned to submit regulatory documents, stakeholders are watching closely for the next regulatory moves that could expand access to this drill-free approach to cavity care.

You might also like:

• Mobile dental lab brings volunteer dentists to care for homeless and vulnerable in the UK
• Root canal treatment reduces heart disease and diabetes risk, study finds
• Transgender children face another experimental treatment amid growing controversy
• Puberty blockers trial must be stopped amid safety and ethics concerns
• FDA approves drug that doubles survival for late-stage pancreatic cancer patients

Michael Thompson

Michael Thompson is an experienced journalist covering U.S. and global news. With ten years on the front lines, he breaks down political and economic stories that matter. His precise writing and keen attention to detail help you grasp the real‑world impact of every event.